First-Line and Maintenance Therapy for Patients with Extensive-Stage Small Cell Lung Cancer — An Interview with Prof Martin Reck

Lung Cancer Update · Jun 18, 2026 · 40:45

Listen in the Podli app 🎧

Follow your favourite podcasts, listen offline and in the car with CarPlay and Android Auto, and always pick up where you left off. Free to try.

Featuring an interview with Prof Martin Reck, including the following topics:

Case: A woman in her mid 70s with extensive-stage small cell lung cancer (ES-SCLC) experiences a strong response to first-line chemoimmunotherapy and maintenance lurbinectedin/atezolizumab (0:00)
Biology of small cell lung cancer and pharmacodynamics of systemic treatment (3:25)
Considerations with maintenance therapy for ES-SCLC (9:31)
Considerations with immunotherapy for ES-SCLC (13:12)
Curability of SCLC with systemic therapy (15:17)
Data with chemoimmunotherapy for patients with poor performance status (25:55)
Future developments in therapy for SCLC (30:11)
Rapid fire: Small Cell 101 (35:45)